Sugi Predict

Sugi Predict / Targets / NAE1

NAE1

NEDD8-activating enzyme E1 regulatory subunit · Q13564 · NAE1 on Sugi Atlas →

7,883 patent compounds predicted against NAE1, 5,480 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL782478 SCHEMBL782478 1.00 20/20
SCHEMBL782622 SCHEMBL782622 1.00 20/20
SCHEMBL782657 SCHEMBL782657 1.00 20/20
SCHEMBL782697 SCHEMBL782697 1.00 20/20
SCHEMBL782713 SCHEMBL782713 1.00 20/20
SCHEMBL782727 SCHEMBL782727 1.00 20/20
SCHEMBL782736 SCHEMBL782736 1.00 20/20
SCHEMBL782768 SCHEMBL782768 1.00 20/20
SCHEMBL782791 SCHEMBL782791 1.00 20/20
SCHEMBL782870 SCHEMBL782870 1.00 20/20
SCHEMBL782888 SCHEMBL782888 1.00 20/20
SCHEMBL783481 SCHEMBL783481 1.00 20/20
SCHEMBL783604 SCHEMBL783604 1.00 20/20
SCHEMBL783611 SCHEMBL783611 1.00 20/20
SCHEMBL783653 SCHEMBL783653 1.00 20/20
SCHEMBL789213 SCHEMBL789213 1.00 20/20
SCHEMBL783605 SCHEMBL783605 0.82 20/20
SCHEMBL783693 SCHEMBL783693 0.82 20/20
SCHEMBL783812 SCHEMBL783812 0.82 20/20
SCHEMBL783523 SCHEMBL783523 0.80 20/20

Clinical trials — most relevant to NAE1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency PHASE3COMPLETED
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome PHASE2COMPLETED
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome PHASE1/PHASE2RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety PHASE2NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas PHASE2COMPLETED
Olaparib in Patients With HRD Malignant Mesothelioma PHASE2RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Clinical and Basic Investigations Into Congenital Disorders of Glycosylation nanRECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome nanACTIVE_NOT_RECRUITING
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study nanRECRUITING
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
MNGIE Natural History Study nanRECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies nanRECRUITING
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING
Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NAE1 binder may also engage these)

ProteinNameSimilarity
Q8VBW6 — 1.000 Q8VBW6 →
Q9Z1A5 — 1.000 Q9Z1A5 →
Q6NTW6 — 1.000 Q6NTW6 →
Q4R3L6 — 1.000 Q4R3L6 →
Q5ZIE6 — 1.000 Q5ZIE6 →
Q7SXP2 — 0.999 Q7SXP2 →
P42744 — 0.997 P42744 →
Q9VTE9 — 0.996 Q9VTE9 →
Q9ZV69 — 0.995 Q9ZV69 →
P93028 — 0.994 P93028 →
O94609 — 0.992 O94609 →
Q8C7R4 — 0.992 Q8C7R4 →
Q54JM3 — 0.992 Q54JM3 →
Q55C16 — 0.992 Q55C16 →
Q9UT93 — 0.992 Q9UT93 →
P31252 — 0.992 P31252 →
P20973 — 0.990 P20973 →
Q8VY78 — 0.990 Q8VY78 →
Q06624 — 0.990 Q06624 →
P92974 — 0.990 P92974 →
P31251 — 0.989 P31251 →
A7KAL8 — 0.989 A7KAL8 →
UBA6 Ubiquitin-like modifier-activating enzyme 6 0.989 landscape →
Q18217 — 0.988 Q18217 →
P79064 — 0.987 P79064 →
A6QXC6 — 0.987 A6QXC6 →
G2XR75 — 0.986 G2XR75 →
P0DI12 — 0.986 P0DI12 →
Q9W3C1 — 0.986 Q9W3C1 →
M7U9B9 — 0.986 M7U9B9 →